Novo Holdings announces 2025 Annual Results Novo Holdings announced its financial results for 2025. Despite a challenging global environment, Novo Holdings has made significant progress on its Strategy 2030 during 2025 and delivered on its priorities. The Novo Holdings Investment Portfolio continued to perform well on both an absolute and relative basis, with a return […]
đź‘ĄLondon Life Sciences Week 2025 The busiest week in European life sciences is approaching and Optimum and Catalyst Advisors are here to help you maximise your week. Download our events schedule here to plan ahead, connect smart, and make every moment count! If you have any additional events that you would like to be included, […]
Last week, Optimum hosted its 17th Annual Healthcare Investor Conference 2025. Held in the heart of London, the event brought together a powerhouse of industry leaders, investors, innovators, and communicators to exchange ideas, explore the market outlook, and tackle the pressing questions facing the life sciences sector. If you missed the day, or just want […]
AMSilk Secures EUR 52M Strategic Financing to Accelerate Commercial Growth AMSilk GmbH has successfully secured EUR 52 million financing led by existing investor ATHOS (AT Newtec), along with strong participation from fellow existing investors MIG Capital and Novo Holdings. The financing will enable AMSilk to scale industrial production and meet global customer demand for its […]
SpliceBio secures $135 Million Series B financing to advance lead program SB-007 in Stargardt disease and expand pipeline of genetic medicines SpliceBio, a clinical-stage genetic medicines company pioneering Protein Splicing to address diseases caused by mutations in large genes, announced the close of a $135 million Series B financing co-led by new investors EQT Life Sciences and Sanofi […]
